The Value of Medical Spending in the United States, 1960–2000

Abstract

On average, the increases in medical spending since 1960 have provided reasonable value. However, the spending increases in medical care for the elderly since 1980 are associated with a high cost per year of life gained. The national focus on the rise in medical spending should be balanced by attention to the health benefits of this increased spending.

Relación en España entre la investigación sanitaria financiada por el Sistema Nacional de Salud y la carga de enfermedad en la comunidad

“…Por tanto, que la carga de enfermedad sea mayor para una condición no implica necesariamente unos mayores beneficios en salud asignando más recursos, del mismo modo que la existencia de intervenciones sanitarias eficaces no garantiza una mejor utilización de las mismas en términos de efectividad, eficiencia o equidad y accesibilidad a las prestaciones sanitarias. Así, sería conveniente considerar algunas de estas variables así como las ganancias potenciales atribuidas a la investigación pudiendo para ello emplearse el número de AVAD evitados u otros índices alternativos 41,42 . A pesar de las limitaciones y dificultades en la medición de estos resultados, la explicación de algunos de estos aspectos podría contribuir a un mejor conocimiento de la investigación realizada en el ámbito del SNS.…”

Comparison of saftey and cost effectiveness of atorvastatin 40 mg daily, rosuvastatin 20 mg daily and rosuvastatin 20 mg alternate day in 300 patients with type 2 diabetes mellitus

“…[19][20][21] The World Health Organization has suggested international cost-effectiveness threshold values of three times the gross domestic product per capital and thresholds up to US$100,000 have been suggested. 22,23 In Sweden, values equivalent to around US$100,000 (about €70,000) have been indicated on the basis of willingness to pay for prevention of road deaths. 24 Based on the average exchange rate for USD to SEK in 2013/14 (avg Rs.…”

Why U.S. health care expenditure and ranking on health care indicators are so different from Canada’s

“…If it is true that Baumol's costs disease is overstated because the "output" used in measuring the productivity in health care fails to capture major improvements in quality (Newhouse 1993;Triplett and Bosworth 2003), focusing on one country give biased results. For example Cutler et al (2006) show that while the cost of medical spending shot up from 1960 to 2000, largely as a result of the development and wide-spread use of new medical techniques, the cost per quality-adjusted life year decreased. However, even if the Baumol's costs disease is overstated, a comparison between countries seems to be justified.…”